JB/CALL/MODERNA/130/0.0166/20.09.24 | Market Closed - Swiss Exchange 11:20:00 2024-06-19 EDT | ||
| 0.25 CHF | -3.85% |
|
| Current month | -41.86% | ||
| 1 month | -3.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-19 | 0.25 | -3.85% |
| 24-06-18 | 0.26 | -13.33% |
| 24-06-17 | 0.3 | -14.29% |
| 24-06-14 | 0.35 | -12.50% |
| 24-06-12 | 0.4 | -4.76% |
Delayed Quote Swiss Exchange
Last update June 19, 2024 at 11:20 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Bank Julius Bär |
| MRZNJB | |
| ISIN | CH1280665535 |
| Date issued | 2023-08-07 |
| Strike | 130 $ |
| Maturity | 2024-09-20 (93 Days) |
| Parity | 60 : 1 |
| Emission price | 0.27 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.68 CHF |
|---|---|
| Lowest since issue | 0.06 CHF |
| Spread | 0.01 CHF |
| Spread % | 4.00% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.3
USD
Average target price
145.2
USD
Spread / Average Target
+8.97%
- Stock Market
- Warrants
- MRZNJB Warrant
